Increased HLA-G Expression in Tissue-Infiltrating Cells in Inflammatory Bowel Diseases

Ferreira, S. E. S.; Sadissou, Ibrahim; Parra, Rogério Serafim; Feitosa, M. R.; Neto, Fermino Sanches Lizarte; Tirapelli, Daniela Pretti da Cunha; Ramalho, Leandra Náira Zambelli; Féres, Omar; Rocha, José Joaquim Ribeiro da; Donadi, Eduardo Antônio; Troncon, Luiz Ernesto de Almeida

doi:10.1007/s10620-020-06561-3

Cited by 5 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By the other hand, a previous study carried out by Costa Ferreira et al to evaluate intestinal mHLA-G expression and soluble HLA-G (sHLA-G) levels in Crohn's disease (CD) and ulcerative colitis (UC) patients, showed that these inflammatory gastric diseases present increased levels of sHLA-G compared to controls. They also report an increased HLA-G expression in inflammatory cells associated with increased sHLA-G levels in both, CD and UC patients, however, HLA-G positive infiltrating cells was greater in UC than in CD samples, suggesting that the increased HLA-G positive inflammatory cells may increase the total plasma sHLA-G levels, (sHLA-G plus HLA-Gev) 33 .…”

Section: Discussionmentioning

confidence: 92%

“…This over-expression of HLA-G may reflect ongoing host strategies to suppress chronic inflammation 33 . Our results, in relation with the sHLA-G expression levels in benign gastric pathologies suggest that ectopic HLA-G expression in benign gastric pathologies could be useful to discriminate a precancerous pathology from other benign diseases, local and systemic mechanisms may be involved in the induction of HLA-G expression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble HLA-G (sHLA-G) measurement might be useful as an early diagnostic biomarker and screening test for gastric cancer

Mejía-Guarnizo,

Monroy-Camacho,

Rincón-Rodríguez

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Gastric cancer (GC) is the fifth most frequent malignancy worldwide and has a high mortality rate related to late diagnosis. Although the gold standard for the GC diagnosis is endoscopy with biopsy, nonetheless, it is not cost-effective and is invasive for the patient. The Human leukocyte antigen G (HLA-G) molecule is a checkpoint of the immune response. Its overexpression in cancer is associated with immune evasion, metastasis, poor prognosis, and lower overall survival. We evaluate the plasma levels of soluble HLA-G, (sHLA-G) in patients with GC and benign gastric pathologies using an ELISA test. A higher concentration of sHLA-G in patients with GC than in those with benign pathologies, higher levels of plasma sHLA-G in women with GC compared with men and significant differences in the sHLA-G levels between the benign gastric pathologies evaluated, was our main findings. As no significant differences were found between the GC assessed stages in our study population, we suggest that sHLA-G is not an adequate marker for staging GC, but it does have diagnostic potential. In addition to providing information on the potential of sHLA-G as a diagnostic marker for GC, our study demonstrate that HLA-G molecules can be found in the membrane of exosomes, which highlights the need to perform studies with a larger number of samples to explore the functional implications of HLA-G positive exosomes in the context of gastric cancer, and to determine the clinical significance and possible applications of these findings in the development of non-invasive diagnostic methods.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Soluble HLA-G (sHLA-G) measurement might be useful as an early diagnostic biomarker and screening test for gastric cancer

Mejía-Guarnizo,

Monroy-Camacho,

Rincón-Rodríguez

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, in many cases further studies are needed to confirm whether the expression alone is the predisposing factor and how the regulatory variation affects differential expression in diseases. Elevated HLA expression levels have been associated with inflammatory bowel diseases ( 56 , 76 ), scleroderma patients with interstitial lung disease ( 77 ), ankylosing spondylitis ( 78 ), Graves’ disease ( 79 ), systemic lupus erythematosus ( 80 ), rheumatoid arthritis ( 72 ), and multiple sclerosis ( 81 ). Additionally, in celiac disease and type 1 diabetes, higher expression of DQA1*05 and DQB1*02 alleles was found in patients when compared to healthy controls ( 82 , 83 ).…”

Section: Hla Expression In Human Diseasesmentioning

confidence: 99%

HLA allele-specific expression: Methods, disease associations, and relevance in hematopoietic stem cell transplantation

2022

View full text Add to dashboard Cite

Varying HLA allele-specific expression levels are associated with human diseases, such as graft versus host disease (GvHD) in hematopoietic stem cell transplantation (HSCT), cytotoxic T cell response and viral load in HIV infection, and the risk of Crohn’s disease. Only recently, RNA-based next generation sequencing (NGS) methodologies with accompanying bioinformatics tools have emerged to quantify HLA allele-specific expression replacing the quantitative PCR (qPCR) -based methods. These novel NGS approaches enable the systematic analysis of the HLA allele-specific expression changes between individuals and between normal and disease phenotypes. Additionally, analyzing HLA allele-specific expression and allele-specific expression loss provide important information for predicting efficacies of novel immune cell therapies. Here, we review available RNA sequencing-based approaches and computational tools for NGS to quantify HLA allele-specific expression. Moreover, we explore recent studies reporting disease associations with differential HLA expression. Finally, we discuss the role of allele-specific expression in HSCT and how considering the expression quantification in recipient-donor matching could improve the outcome of HSCT.

show abstract

HLA-G: A Novel Immune Checkpoint for Solid Cancer Immunotherapy

Lin

Yan

2023

Handbook of Cancer and Immunology

View full text Add to dashboard Cite

Increased HLA-G Expression in Tissue-Infiltrating Cells in Inflammatory Bowel Diseases

Cited by 5 publications

References 25 publications

Soluble HLA-G (sHLA-G) measurement might be useful as an early diagnostic biomarker and screening test for gastric cancer

Soluble HLA-G (sHLA-G) measurement might be useful as an early diagnostic biomarker and screening test for gastric cancer

HLA allele-specific expression: Methods, disease associations, and relevance in hematopoietic stem cell transplantation

HLA-G: A Novel Immune Checkpoint for Solid Cancer Immunotherapy

Contact Info

Product

Resources

About